CliffBio
small molecule

SELEXIPAG

SELEXIPAG

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameSELEXIPAG
Active ingredientSELEXIPAG
Strength1.6MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2023
Marketing statusRX

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.